Mnemosyne Pharmaceuticals has changed its name to Luc Therapeutics Inc. to better reflect its overall synaptic plasticity-oriented drug development strategy. The new Luc Therapeutics will be headquartered in Cambridge, MA. “Changing our name to Luc Therapeutics reflects the tremendous progress we have made to focus our discovery capabilities on areas where NMDA receptor modulation offers the most tractable path to potential therapeutics for patients,” said Vanessa King, president and chief ex...